HC Wainwright & Co. Reiterates Buy on Kronos Bio, Maintains $2.25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns reiterates a Buy rating on Kronos Bio (NASDAQ:KRON) and maintains a $2.25 price target.
August 01, 2024 | 10:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reiterates a Buy rating on Kronos Bio and maintains a $2.25 price target.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100